192 related articles for article (PubMed ID: 34520479)
21. Ribonuclear foci at the neuromuscular junction in myotonic dystrophy type 1.
Wheeler TM; Krym MC; Thornton CA
Neuromuscul Disord; 2007 Mar; 17(3):242-7. PubMed ID: 17306536
[TBL] [Abstract][Full Text] [Related]
22. Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1).
Gladman JT; Mandal M; Srinivasan V; Mahadevan MS
PLoS One; 2013; 8(9):e72907. PubMed ID: 24039817
[TBL] [Abstract][Full Text] [Related]
23. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
[TBL] [Abstract][Full Text] [Related]
24. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
[TBL] [Abstract][Full Text] [Related]
25. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
[TBL] [Abstract][Full Text] [Related]
26. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
[TBL] [Abstract][Full Text] [Related]
27. Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I.
Herrendorff R; Faleschini MT; Stiefvater A; Erne B; Wiktorowicz T; Kern F; Hamburger M; Potterat O; Kinter J; Sinnreich M
J Biol Chem; 2016 Aug; 291(33):17165-77. PubMed ID: 27298317
[TBL] [Abstract][Full Text] [Related]
28. In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models.
García-López A; Llamusí B; Orzáez M; Pérez-Payá E; Artero RD
Proc Natl Acad Sci U S A; 2011 Jul; 108(29):11866-71. PubMed ID: 21730182
[TBL] [Abstract][Full Text] [Related]
29. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts.
Fardaei M; Larkin K; Brook JD; Hamshere MG
Nucleic Acids Res; 2001 Jul; 29(13):2766-71. PubMed ID: 11433021
[TBL] [Abstract][Full Text] [Related]
30. Defining early steps in mRNA transport: mutant mRNA in myotonic dystrophy type I is blocked at entry into SC-35 domains.
Smith KP; Byron M; Johnson C; Xing Y; Lawrence JB
J Cell Biol; 2007 Sep; 178(6):951-64. PubMed ID: 17846170
[TBL] [Abstract][Full Text] [Related]
31. Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy.
Wojciechowska M; Sobczak K; Kozlowski P; Sedehizadeh S; Wojtkowiak-Szlachcic A; Czubak K; Markus R; Lusakowska A; Kaminska A; Brook JD
Sci Rep; 2018 Apr; 8(1):5885. PubMed ID: 29651162
[TBL] [Abstract][Full Text] [Related]
32. Altered nuclear structure in myotonic dystrophy type 1-derived fibroblasts.
Rodríguez R; Hernández-Hernández O; Magaña JJ; González-Ramírez R; García-López ES; Cisneros B
Mol Biol Rep; 2015 Feb; 42(2):479-88. PubMed ID: 25307018
[TBL] [Abstract][Full Text] [Related]
33. New function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeats.
Laurent FX; Sureau A; Klein AF; Trouslard F; Gasnier E; Furling D; Marie J
Nucleic Acids Res; 2012 Apr; 40(7):3159-71. PubMed ID: 22156369
[TBL] [Abstract][Full Text] [Related]
34. Gain of RNA function in pathological cases: Focus on myotonic dystrophy.
Klein AF; Gasnier E; Furling D
Biochimie; 2011 Nov; 93(11):2006-12. PubMed ID: 21763392
[TBL] [Abstract][Full Text] [Related]
35. Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple Mechanisms.
Jenquin JR; Coonrod LA; Silverglate QA; Pellitier NA; Hale MA; Xia G; Nakamori M; Berglund JA
ACS Chem Biol; 2018 Sep; 13(9):2708-2718. PubMed ID: 30118588
[TBL] [Abstract][Full Text] [Related]
36. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.
Mankodi A; Logigian E; Callahan L; McClain C; White R; Henderson D; Krym M; Thornton CA
Science; 2000 Sep; 289(5485):1769-73. PubMed ID: 10976074
[TBL] [Abstract][Full Text] [Related]
37. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2.
Mankodi A; Urbinati CR; Yuan QP; Moxley RT; Sansone V; Krym M; Henderson D; Schalling M; Swanson MS; Thornton CA
Hum Mol Genet; 2001 Sep; 10(19):2165-70. PubMed ID: 11590133
[TBL] [Abstract][Full Text] [Related]
38. Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.
Yadava RS; Yu Q; Mandal M; Rigo F; Bennett CF; Mahadevan MS
Hum Mol Genet; 2020 Jun; 29(9):1440-1453. PubMed ID: 32242217
[TBL] [Abstract][Full Text] [Related]
39. HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence.
Kim DH; Langlois MA; Lee KB; Riggs AD; Puymirat J; Rossi JJ
Nucleic Acids Res; 2005; 33(12):3866-74. PubMed ID: 16027111
[TBL] [Abstract][Full Text] [Related]
40. Myotonic dystrophy associated expanded CUG repeat muscleblind positive ribonuclear foci are not toxic to Drosophila.
Houseley JM; Wang Z; Brock GJ; Soloway J; Artero R; Perez-Alonso M; O'Dell KM; Monckton DG
Hum Mol Genet; 2005 Mar; 14(6):873-83. PubMed ID: 15703191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
